Basit öğe kaydını göster

dc.contributor.authorGul, Serdar
dc.contributor.authorKuscu, Ferit
dc.contributor.authorAydemir, Hande
dc.contributor.authorOzturk, Dogan Baris
dc.contributor.authorDeveci, Ozcan
dc.contributor.authorDuygu, Fazilet
dc.contributor.authorAslan, Emel
dc.date.accessioned2020-06-25T18:16:45Z
dc.date.available2020-06-25T18:16:45Z
dc.date.issued2016
dc.identifier.citationGul, S., Kuscu, F., Aydemir, H., Ozturk, D. B., Deveci, O., Duygu, F., Kacmaz, B., Yaman, F., & Aslan, E. (2016). Risk Factors for Colistin-Associated Acute Kidney Injury: A Multicenter Study from Turkey. Japanese journal of infectious diseases, 69(2), 109–112.en_US
dc.identifier.issn1344-6304
dc.identifier.issn1884-2836
dc.identifier.urihttps://doi.org/10.7883/yoken.JJID.2014.501
dc.identifier.urihttps://hdl.handle.net/20.500.12587/6615
dc.descriptionYaman, Ferda/0000-0001-6847-1720; Kuscu, Ferit/0000-0001-5662-8305en_US
dc.descriptionWOS: 000373245600004en_US
dc.descriptionPubMed: 26166495en_US
dc.description.abstractThe aim of this study was to investigate the incidence of acute kidney injury (AKI) and risk factors due to colistin use in patients infected with multidrug-resistant pathogens. This multicenter, retrospective, observational study was conducted in Turkey, at 5 different research and university hospitals. Cox regression analyses were performed, to determine independent predictors of AKI. From April 2012 to July 2014, a total of 216 patients aged between 18-94 years, treated with colistimethate sodium (CMS) were included in the study. The mean age of the patients was 60.3 +/- 20.1 years. The overall incidence of AKI was 34.3% (74/216) at any time during treatment. Concomitant use of loop diuretics, baseline creatinine level, and CMS dosage were independently associated with AKI. According to our results, patients with higher baseline creatinine levels, or patients who had to use concomitant loop diuretics may need to be monitored more closely, and dose adjustment should be done promptly. More comprehensive studies are, however, still needed to evaluate the efficacy of low-dose colistin since higher doses tend to increase the risk of AKI.en_US
dc.language.isoengen_US
dc.publisherNatl Inst Infectious Diseasesen_US
dc.relation.isversionof10.7883/yoken.JJID.2014.501en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleRisk Factors for Colistin-Associated Acute Kidney Injury: A Multicenter Study from Turkeyen_US
dc.typearticleen_US
dc.contributor.departmentKırıkkale Üniversitesien_US
dc.identifier.volume69en_US
dc.identifier.issue2en_US
dc.identifier.startpage109en_US
dc.identifier.endpage112en_US
dc.relation.journalJapanese Journal Of Infectious Diseasesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster